Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma

BACKGROUND: MAPK inhibitors (MAPKi) are active in BRAF-mutant metastatic melanoma patients, but the extent of response and progression-free survival (PFS) is variable, and complete responses are rare. We sought to examine the patterns of response and progression in patients treated with targeted the...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzies, Alexander M., Haydu, Lauren E., Carlino, Matteo S., Azer, Mary W. F., Carr, Peter J. A., Kefford, Richard F., Long, Georgina V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882277/
https://www.ncbi.nlm.nih.gov/pubmed/24400126
http://dx.doi.org/10.1371/journal.pone.0085004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882277/
https://www.ncbi.nlm.nih.gov/pubmed/24400126
http://dx.doi.org/10.1371/journal.pone.0085004

Ejemplares similares